Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Meso phase II/III trial of nintedanib plus pemetrexed/cisplatin in unresectable malignant pleural mesothelioma
MOH_2017-05-11_000409Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing Nintedanib arm with Placebo arm (2 arms). Started Feb 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on MOH_2017-05-11_000409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-11_000409.